Companies Partner to Develop Medical Countermeasures for Nuclear and Radiological Threats

July 31, 2007
Osiris Therapeutics and Genzyme Corp. have formed a partnership to adapt a leading stem cell therapy as a countermeasure to nuclear terrorism and other radiological emergencies. The initial focus of the partnership will be to develop Prochymal, a formulation of adult stem cells derived from bone marrow, to treat the potentially lethal complications of acute radiation syndrome (ARS).

Prochymal currently is in Phase III clinical trials for the treatment of GvHD and Crohn’s Disease and has demonstrated preliminary efficacy in the treatment of patients experiencing first-time heart attacks. These trials have shown Prochymal’s potential to reverse cellular damage and improve survival in disease states similar to ARS.

"After an extensive evaluation of the indication, product and process, we are properly positioned to launch this major new initiative," said C. Randal Mills, Ph.D., president and CEO of Osiris. “Our scientists recognized an opportunity to efficiently enter this new market by leveraging the significant overlap that exists between our ongoing development activities for Prochymal and the requirements demanded of an ARS product. We then assembled a team that would give us the greatest chance for success. The resources and capabilities of Genzyme fit very well with this initiative.”

Currently, Prochymal is the only stem cell therapy to have been granted Fast Track status by FDA.

“Based upon the clinical data generated by Osiris, coupled with our own internal research, we believe there is potential for Prochymal to be of significant therapeutic benefit to patients suffering the effects of ARS,” said John M. McPherson, senior vice president and head of biologics research and development, Genzyme Corp.

More information about Prochymal and its development for ARS can be found on the Osiris Web site at

Sponsored Recommendations

ISO 45001: Occupational Health and Safety Management Systems (OHSMS)

March 28, 2024
ISO 45001 certification – reduce your organizational risk and promote occupational health and safety (OHS) by working with SGS to achieve certification or migrate to the new standard...

Want to Verify your GHG Emissions Inventory?

March 28, 2024
With the increased focus on climate change, measuring your organization’s carbon footprint is an important first action step. Our Green House Gas (GHG) verification services provide...

Download Free ESG White Paper

March 28, 2024
The Rise and Challenges of ESG – Your Journey to Enhanced Sustainability, Brand and Investor Potential

Free Webinar: Mining & ESG: The Sustainability Mandate

March 28, 2024
Participants in this webinar will understand the business drivers and challenges of ESG and sustainability performance, the 5 steps of the ESG and sustainability cycle, and prioritized...

Voice your opinion!

To join the conversation, and become an exclusive member of EHS Today, create an account today!